Promising drug cocktail takes on tough lymphoma
NCT ID NCT06558604
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of three drugs—glofitamab, venetoclax, and zanubrutinib—in people with high-risk mantle cell lymphoma, either newly diagnosed or after relapse. The study will enroll 100 participants across three groups based on their treatment history. The main goal is to see if the combo can keep the cancer from progressing for at least 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glofitamab, venetoclax, and zanubrutinib (drugs)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat mantle cell lymphoma, potentially improving how long they live without their cancer getting worse.
- What could go wrong
- This is an early-phase trial with only 100 people, so results may not apply to everyone. The drug combination can cause serious side effects, and it is not yet known if it works better than current treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, MANTLE-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aphp - Hopital Henri Mondor
RECRUITINGCréteil, France
-
Az Sint-Jan Brugge - Oostende Av
RECRUITINGBruges, Belgium
-
Centre Henri Becquerel
RECRUITINGRouen, France
-
Chu Dijon Bourgogne
RECRUITINGDijon, France
-
Chu Lyon-Sud
RECRUITINGPierre-Bénite, France
-
Chu Pontchaillou
RECRUITINGRennes, France
-
Chu Ucl Namur - Site Godinne
RECRUITINGYvoir, Belgium
-
Chu de Liege
RECRUITINGLiège, Belgium
-
Chu de Lille - Hopital Claude Huriez
RECRUITINGLille, France
-
Chu de Montpellier
RECRUITINGMontpellier, France
-
Chu de Nantes
RECRUITINGNantes, France
-
Chu de Reims - Hopital Robert Debre
RECRUITINGReims, France
-
Hopitaux Universitaires de Strasbourg (Hus)
RECRUITINGStrasbourg, France
-
Institut Curie
RECRUITINGSaint-Cloud, France
-
Institut Jules Bordet
RECRUITINGBrussels, Belgium
-
Institut Paoli Calmettes
RECRUITINGMarseille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for blood cancer patients: experimental drug takes on standard therapy
- Can a smart patch predict dangerous immune reactions in cancer treatment?
- 15-Year watch begins for CAR t cell therapy patients
- New drug MTM-H-001 takes on tough blood cancers
- New pill shows promise for Hard-to-Treat blood cancers
- New targeted combo aims to slow mantle cell lymphoma